Diagnosis and treatment of acute myelogenous leukemia in childhood

Critical Reviews in Oncology/Hematology

Volumn 22, Issue 3, 1996, Pages 183-196

  Creutzig, Ursula ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; CYTARABINE; CYTARABINE TRIPHOSPHATE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; BONE MARROW SUPPRESSION; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHILD; DIFFERENTIAL DIAGNOSIS; DOWN SYNDROME; HUMAN; LEUKOSTASIS; MYELODYSPLASTIC SYNDROME; REVIEW;

EID: 0029994457     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00195-3     Document Type: Review

References (78)

1. Alcalay M, Zangilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, et al. Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor alpha locus. Proc Natl Acad Sci USA 88:1977-1981, 1991.
2. Amadori S, Testi AM, Aricó M, Comelli A, Giuliano M, Madon E, et al. Prospective comparative study of bone marrow transplantation and post-remission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 11:1046-1054, 1993.
3. Appelbaum FR, Fisher LD, Thomas ED. Chemotherapy versus marrow transplantation for adults with acute nonlymphocytic leukemia: a five-year follow-up. Blood 72:179-184, 1988.
4. Baehner RL, Bernstein ID, Sather H, Higgins G, McCreadie S, Chard RL, et al. Contrasting benefits of two maintenance programs following identical induction in children with acute nonlymphocytic leukemia: a report from the Childrens Cancer Study Group. Cancer Treat Rep 68:1269-1272, 1984.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 78:325-329, 1991.
6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. Br J Haematol 33:451-458, 1976.
7. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the myelodysplastic sydromes. Br J Haematol 51:189-199, 1982.
8. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103:626-629, 1985.
9. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med 103:460-462, 1985.
10. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77:1666-1674, 1991.
11. Bishop JF, Young GA, Szer J. Randomized trial of high dose cytosine arabinoside (Ara-C) combination in induction in acute myeloid leukemia (AML). Proc ASCO 11:849, 1992.
12. Boos J, Schiller M, Pröbsting B, Creutzig U, Ritter J. Intracellular retention of cytosine arabinoside-triphosphate in leukemic blast cells from children. Ann Hematol 68 (Suppl. I): A23, 1994 (Abstract).
13. Brandwein JE, Horsman DE, Eaves AC, Eaves CJ, Massing BG, Eaves AC, Wadsworth LD, Rogers PCJ, Kalousek DK. Childhood myelodysplasia: suggested classification as myelodysplastic syndromes based on laboratory and clinical findings. Am J Pediatr Hematol Oncol 12:63, 1990.
14. Brochstein J, Kernan NA, Groshen S. Allogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia. New Engl J Med 317:1618-1624, 1987.
15. Buckley JD, Chard RL, Bachner RL, Nesbit ME, Lampkin BC, Woods WG, et al. Improvement in outcome for children with acute nonlymphocytic leukemia. A report form the Children's Cancer Study Group. Cancer 63:1457-1465, 1989.
16. Büchner T. Acute leukemia. Curr Opin Hematol 172-182, 1993.
17. Büchner T, Hiddemann W, Koenigsmann M, Zühlsdorf M, Wörmann B, Boeckmann A, et al. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood 78:1190-1197, 1991.
18. Büchner T, Hiddemann W, Löffler G, Gassmann W, Maschmeyer G, Heit W, et al. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Semin Hematol 28:76-79, 1991.
19. Büchner T, Hiddemann W, Rottmann R, Wörmann B, Zühlsdorf M, Maschmeyer G, et al. GM-CSF in chemotherapy for newly diagnosed AML: multiple course priming and long-term administration compared to chemotherapy alone. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, eds. Acute Leukemias IV. New York: Springer, 1993; 138-141.
20. Büchner T, Hiddemann W, Wörmann B, Maschmeyer G, Heit W, Aul C, et al. Chemotherapy intensity and long-term outcome in AML. In: Büchner et al. eds. Acute Leukemias IV, Prognostic Factors. New York: Springer Verlag, 1994; 513-518.
21. Busca A, Anasetti C, Anderson G, Appelbaum FR, Buckner CD, Doney K, Martin PJ, Petersdorf E, Sanders JE, Hansen JA. Unrelated donor or autologous marrow transplantation for treatment of acute leukemia. Blood 83:3077-3084, 1994.
22. Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, et al. Varying intensity of post-remission therapy in acute leukemia. Blood 79:1924-1930, 1992.
23. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709, 1990.
24. Cheson BD. Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, et al. Report of the National Cancer Institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol 8:813-819, 1990.
25. Cline MJ. The molecular basis of leukemia. New Engl J Med 330:328-336, 1994.
26. Creutzig U, Bender-Götze C, Klingebiel T, Ebell W, Friedrich W, Stollmann-Gibbels B, et al. Vergleich der alleinigen Chemotherapie mit der allogenen Knochenmarktransplantation in erster Vollremission bei Kindern mit akuter myeloischer Leukämie in den Studien AML-BFM-83 und AML-BFM-87-Matched Pair Analyse. Klin Pädiatr 204:246-252, 1992.
27. Creutzig U, Cantù-Rajnoldi A, Ritter J, Romitti L, Odenwald E, Conter V, et al. Myelodysplastic syndromes in childhood: report of 21 patients from Italy and West-Germany. Am J Pediatr Hematol Oncol 9:324-330, 1987.
28. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia: associations with hyperleukocytosis and acute monocytic leukemia. Cancer 60:3071-3079, 1987.
29. Creutzig U, Ritter J, Riehm H, Langermann H-J, Henze G, Kabisch H, et al. Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78. Blood 65:298-304, 1985.
30. Creutzig U, Ritter J, Schellong G. Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in the study AML-BFM-83 as compared with study AML-BFM-78. Blood 75:1932-1940, 1990.
31. Creutzig U, Ritter J, Schellong G, for the AML-BFM Study Group. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia (AML): unexpected results of the childhood AML Study BFM-87. J Clin Oncol 11:279-286, 1993.
32. Creutzig U, Harbott J, Sperling Ch, Ritter J, Zimmermann M, Löffler H, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: Results of Study AML-BFM-87. Blood 86:3097-3108, 1995.
33. Dahl GV, Kalwinsky DK, Mirro J Jr., Look AT, Pui CH, Murphy SB, et al. Allogeneic bone marrow transplantation in a program of intensive sequential chemotherapy for children and young adults with acute nonlymphocytic leukemia in first remission. J Clin Oncol 8:295-303, 1990.
34. Dahl GV, Simone JV, Hustu HO, Mason C. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer 42:2187-2192, 1978.
35. Estey E, Thall PF, Kantarjian H, O'Brian S, Koller CA, Beran M, et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood 79:2246-2255, 1992.
36. Feig SA, Lampkin B, Nesbit ME, Woods WG, Versteeg CM, Buckley JD, et al. Outcome of BMT during first complete remission of AML: a comparison of two sequential studies by the Childrens Cancer Group. Bone-Marrow Transplant 12:65-71, 1993.
37. Fenaux P, Castaigne S, Chomienne C, Dombret H, Degos L, All trans retinoic acid treatment for patients with acute promyelocytic leukemia. Leukemia 6:64-67, 1992.
38. Foon KA, Gale RP. Acute myelogenous leukemia: current status of therapy in adults. Recent Results Cancer Res 93:216-239, 1984.
39. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrel RP, Jr. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 117:292-296, 1992.
40. Gorín NC, Aegerter P, Auvert B, Meloni B, Goldstone AH, Burnett A, et al. Autologous bone marrow transplantation for acute myelogenous leukemia in first remission: a European survey of the role of marrow purging. Blood 75:1606-1614, 1990.
41. Grier HE, Gelber RD, Clavell LA, Camitta BM, Link MP, Garcea MJ, et al. Intensive sequential chemotherapy for children with acute myelogenous leukemia. Haematol Blood Transf 33:193-197, 1990.
42. Griffin JD, Young D, Hermann F, Wiper D, Wagner K, Sabbath KD. Effects of recombinant human GM-CSF on proliferation of clonogenic cells in acute myeloblastic leukemia. Blood 67:1448-1453, 1986.
43. Groch SN, Sayre GP, Heck FJ. Cerebral hemorrhage in leukemia. Arch Neurol Chicago 2:439-451, 1960.
44. Hasle H. Myelodysplastic syndromes in childhood - classification, epidemiology, and treatment. Leuk Lymph 13:11-26, 1994.
45. Hoang T, Nara N, Wong G, Clark S, Minden MD, McCulloch EA, Effects of recombinant GM-CSF on the blast cells of acute myeloblastic leukemia. Blood 68:313-316, 1986.
46. Hows J, Bradley BA, Gore S, Downie T, Howard M, Gluckman E, et al. Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplant 12:371-380, 1993.
47. Iurlo A, Mecucci C, van Orshoven A, Michaux JL, Boogaerts M, Noens L, et al. Cytogenetic and clinical investigations in 76 cases with therapy-related leukemia and myelodysplastic syndrome. Cancer Genet Cytogenet 43:227-243, 1989.
48. Jäger U. Detection of AML1/ETO rearrangements in acute myeloid leukemia with a translocation t(8;21). Ann Hematol 86 (Suppl. I):A54, 1994 (Abstract).
49. Kay HEM. Development of CNS leukaemia in acute myeloid leukaemia in childhood. Arch Dis Child 51:73-77, 1976.
50. Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, et al. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood 82:1270-1276, 1993.
51. Lange B, Woods W, Lampkin B, Nesbit M, Feig S, Wells R, et al. Childrens Cancer Group transplant trials for acute myeloid leukemia in children: a cross-study analysis of CCG-251, CCG-213, CCG-2861, and CCG-2891. In: Büchner T, Hiddemann W, Wörmann B, Ritter J, Schellong G, eds. Acute Leukemias IV. New York: Springer, 1993; 724-733.
52. Lie SO. Acute myelogenous leukaemia in children. Eur J Pediatr 148:382-388, 1991.
53. Mandelli F, Vegna ML, Avvisati G, et al. A randomized study of the efficacy of post-consolidation therapy in adult acute nonlymphocytic leukemia: a report of the Italian Cooperative Group GIMEMA. Ann Hematol 64:166-172, 1992.
54. Michel G, Gluckman E, Blaise D, Esperou Bourdeau H, Vernant JP, Kuentz M, et al. Improvement in outcome for children receiving allogeneic bone marrow transplantation in first remission of acute myeloid leukemia: a report from the Groupe d'Etude des Greffes de Moelle Osseuse. J Clin Oncol 10:1865-1869, 1992.
55. Miller WH, Kakizuka A, Frankel SR. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:2694-2698, 1992.
56. Nesbit ME, Buckley JD, Feig SA, Anderson JR, Lampkin B, Bernstein ID, et al. Chemotherapy for induction of remission of childhood acute myeloid leukemia followed by marrow transplantation or multiagent chemotherapy - A report from the Children's Cancer Group. J Clin Oncol 12:127-135, 1994.
57. Pinkel D, Simone J, Hustu HO, Aur RJ. Nine years experience with 'total therapy' of childhood acute lymphocytic leukemia. Pediatrics 50:246-251, 1972.
58. Preisler HD, Rustum Y, Henderson ES, Bjornsson S, Creaven PJ, Higby DJ, et al. Treatment of acute nonlymphocytic leukemia: use of an anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimens. Blood 53:455-464, 1979.
59. Pui CH, Dahl GV, Kalwinsky DK, Look AT, Mirro J, Dodge RK, et al. Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 66:1062-1067, 1985.
60. Rai KR, Holland JF, Glidewell OJ, Weinberg V, Brunner K, Obrecht JP, et al. Treatment of acute myelocytic leukemia: a study by Cancer and Leukemia Group B. Blood 58:1203-1212, 1981.
61. Ravindranath Y, Abella E, Krischer JP, Wiley J, Inoue S, Harris M, et al. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: experience on Pediatric Oncology Group AML Study 8498. Blood 80:2210-2214, 1992.
62. Ravindranath Y, Steuber CP, Krischer J, Civin CI, Ducore J, Vega R, et al. High-dose cytarabine for intensification of early therapy of childhood acute myeloid leukemia: a pediatric oncology group study. J Clin Oncol 9:572-580, 1991.
63. Ravindranath Y, Yeager A, Krischer J, Steuber CP, Pole G, Camitta B, el al. Intensive consolidation chemotherapy (ICC) vs purged autologous bone marrow transplantation (ABMT) early remission for treatment of childhood acute myeloid leukemia (AML): preliminary results of Pediatric Oncology Group (POG) Study 8821. Proc ASCO 1994 (Abstract).
64. Schrappe M, Beck J, Brandeis WE, Feickert HJ, Gadner H, Graf N, et al. Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81. Klin Pädiatr 199:133-150, 1987
65. Slordahl SH, Smeland EB, Holte H, Gronn M, Lie SO, Seip M. Leukemic blasts with markers of four cell lineages in Down's syndrome ('Megaryoblastic Leukemia'). Med Pediatr Oncol 21:254-258, 1993.
66. Sutor AH, Kremens B, Creutzig U, Ritter J, Schellong G. Haemostase- und Fibrinolyseparameter bei akuter myeloischer Leukämie (AML) im Kindesalter. In: van de Loo J, Asbeck F, eds. Haemostase, Thrombophilie und Arteriosklerose. Schattauer Verlag, 1982; 340-343.
67. Tobelem G, Jacquillat C, Chastang C, Auclerc MF, Lechevallier T, Weil M, et al. Acute monoblastic leukemia: a clinical and biological study of 74 cases. Blood 55:71-76, 1980.
68. Vogler WR. Strategies in the treatment of acute myelogenous leukemia. Leuk Res 16:1141-1153, 1992.
69. Warrell RM, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (All-trans-retinoic acid). New Engl J Med 324:1385-1393, 1991.
70. Weinstein H, Mayer R, Rosenthal D, et al. Chemotherapy for acute myelogenous leukemia in children and adults. VAPA update. Blood 62:315-319, 1983.
71. Weinstein H, Ravindranath Y, Krischer J, Steuber CP, Civin C, Gresik M, et al. Early intensive chemotherapy for children with acute myeIogenous leukemia: The Pediatric Oncology Group Experience (1981-1991). In: Büchner T, Hiddemann W, Wörmann B, Ritter J, Schellong G, eds. Acute Leukemias IV. New York: Springer, 1993: 713-715.
72. Wells RJ, Woods WG, Lampkin BC, Nesbit ME, Lee JW, Buckley JD, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol 11:538-545, 1993.
73. Wiernik PH, Dutcher JP, Todd M, Duffy T, Calliendo G, Benson L. Polyethylene glycolated (PEG) interleukin-2 (IL2) as maintenance therapy for acute myelogenous leukemia (AML) in second remission (CR). Blood 78:42a-(Abstract), 1991.
74. Wolff S, Herzig R, Fay J, Phillips GL, Lazarus HM, Flexner JM, et al. High dose cytosine arabinoside and daunomycin as consolidation therapy for acute non-myeloid leukemia in first remission: long-term results. J Clin Oncol 7:1260-1267, 1989.
75. Woods WG, Ruymann FB, Lampkin BC, Buckley JD, Bernstein ID, Srivastana AK, et al. The role of timing of high-dose cytosine arabinoside intensification and of maintenance therapy in the treatment of children with acute non-lymphocytic leukemia. Cancer 66:1106-1113, 1990.
76. Yates JG, Glidewell O, Wiernik P, Cooper MR, Steinberg D, Dosik H, et al. Cytosine arabinoside with daunorubicin or adriamycm for therapy of acute myelocytic leukemia: a CALGB study. Blood 60:454-462, 1982.
77. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK, et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo treatment with 4-hydroperoxycyclophosphamide. New Engl J Med 315:141-147, 1986.
78. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: a review. Prog Clin Biol Res 246:33-56, 1987